Natixis purchased a new stake in shares of West Pharmaceutical Services Inc. (NYSE:WST) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 2,551 shares of the medical instruments supplier’s stock, valued at approximately $253,000.

A number of other hedge funds also recently made changes to their positions in the stock. Mason Street Advisors LLC raised its position in West Pharmaceutical Services by 1.6% during the first quarter. Mason Street Advisors LLC now owns 37,161 shares of the medical instruments supplier’s stock valued at $3,281,000 after acquiring an additional 579 shares in the last quarter. Quest Investment Management LLC increased its position in shares of West Pharmaceutical Services by 2.2% in the first quarter. Quest Investment Management LLC now owns 28,316 shares of the medical instruments supplier’s stock valued at $2,500,000 after buying an additional 609 shares in the last quarter. Janney Montgomery Scott LLC increased its position in shares of West Pharmaceutical Services by 14.1% in the second quarter. Janney Montgomery Scott LLC now owns 4,926 shares of the medical instruments supplier’s stock valued at $489,000 after buying an additional 609 shares in the last quarter. Whittier Trust Co. of Nevada Inc. increased its position in shares of West Pharmaceutical Services by 31.6% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 2,624 shares of the medical instruments supplier’s stock valued at $261,000 after buying an additional 630 shares in the last quarter. Finally, Federated Investors Inc. PA increased its position in shares of West Pharmaceutical Services by 2.4% in the second quarter. Federated Investors Inc. PA now owns 29,835 shares of the medical instruments supplier’s stock valued at $2,962,000 after buying an additional 691 shares in the last quarter. Institutional investors own 95.97% of the company’s stock.

West Pharmaceutical Services stock opened at $122.77 on Tuesday. The company has a market capitalization of $8.94 billion, a PE ratio of 44.16, a price-to-earnings-growth ratio of 4.13 and a beta of 1.20. West Pharmaceutical Services Inc. has a 12 month low of $82.74 and a 12 month high of $124.51. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.67 and a quick ratio of 1.94.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, July 26th. The medical instruments supplier reported $0.70 EPS for the quarter, beating the Zacks’ consensus estimate of $0.67 by $0.03. The business had revenue of $447.50 million during the quarter, compared to analysts’ expectations of $422.57 million. West Pharmaceutical Services had a return on equity of 15.38% and a net margin of 8.99%. The business’s revenue was up 12.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.66 earnings per share. equities analysts predict that West Pharmaceutical Services Inc. will post 2.82 EPS for the current fiscal year.

In other news, SVP Karen Flynn sold 20,458 shares of the business’s stock in a transaction that occurred on Tuesday, August 7th. The stock was sold at an average price of $116.23, for a total value of $2,377,833.34. Following the completion of the sale, the senior vice president now directly owns 31,051 shares in the company, valued at $3,609,057.73. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.70% of the stock is owned by insiders.

A number of research firms have recently commented on WST. Zacks Investment Research upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $123.00 price objective for the company in a research report on Tuesday, July 31st. ValuEngine upgraded West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research report on Tuesday, June 12th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the stock. West Pharmaceutical Services has an average rating of “Hold” and an average target price of $107.00.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Featured Article: What are the reasons investors use put options?

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.